3176 results for «382»
3176 results
Featured research - Tricuspid valve intervention: the TRIPLACE registry
17 Nov 2025 – From PCR London Valves 2025
This session features cutting-edge research on tricuspid valve interventions, including insights from the TRIPLACE registry on orthotopic TTVR thrombosis, predictive value of three-dimensional tricuspid annulus measurements for procedural outcomes, early clinical experiences with novel TTVR systems, and procedural clipping strategies based on results from the BRIGHT...
Left atrial appendage occlusion
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities and innovations in left atrial appendage occlusion (LAAO) procedures. It covers transesophageal ICE monitoring, challenges posed by existing atrial septal occluders, combined surgical and percutaneous approaches, and the practical experience with the Ultraseal device. These insights advance understanding of procedural...
Featured research - TAVI: Predictive tools, AI innovation and reintervention strategies
17 Nov 2025 – From PCR London Valves 2025
This session presents cutting-edge research in TAVI, covering the development of predictive models for clinical valve thrombosis, comparative analyses between self-expandable and balloon-expandable valves from the Greek TAVI registry, and the emerging role of AI-guided Heart Team decisions. It also examines outcomes of reintervention strategies following...
TAVI: complex vascular access
17 Nov 2025 – From PCR London Valves 2025
This session addresses the challenges of complex vascular access in transcatheter aortic valve implantation (TAVI). It discusses strategies for navigating difficult thoraco-abdominal aortic anatomies, managing double aortic arches, and overcoming hostile femoral access. Case studies illustrate meticulous planning and innovative solutions essential for successful TAVI in...
TAVI valve-in-valve - Challenging clinical scenarios
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities of valve-in-valve TAVI procedures, highlighting challenging clinical scenarios such as managing severely regurgitant rapid deployment valves and degenerated stentless bioprostheses. It provides detailed insights into overcoming procedural barriers and strategies for complex valve-in-valve transcatheter aortic valve replacement (TAVR) interventions.
TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture
17 Nov 2025 – From PCR London Valves 2025
This session presents critical case analyses of complicated TAVI procedures, highlighting unexpected and severe intra-procedural events such as annular perforation, leaflet modification complications, coronary obstructions, and device failures. It emphasizes prevention strategies, bailout techniques, and acute management to prepare clinicians for handling TAVI-related emergencies effectively.
TAVI: alternative access
17 Nov 2025 – From PCR London Valves 2025
This session addresses alternative access routes for TAVI in patients with challenging vascular anatomies. It includes innovative approaches such as transapical TAV-in-TAV procedures, transcaval implantation in emergency settings, and techniques for patients with hostile iliofemoral access, showcasing adaptive strategies when conventional access is not feasible.
TAVI: challenging anatomies
17 Nov 2025 – From PCR London Valves 2025
This session explores the management of challenging anatomical conditions in TAVI procedures. Topics include strategies for difficult self-expandable valve delivery angles, addressing complications occurring during and after TAVI, and approaches for patients with severe kyphosis or complex structural abnormalities such as aneurysms and septal anomalies.
Challenging mitral TEER: Barlow's disease, fibro-elastic deficiency & abnormal valve morphology
17 Nov 2025 – From PCR London Valves 2025
This session examines the feasibility and technical considerations of mitral transcatheter edge-to-edge repair (TEER) in complex anatomical and pathological scenarios. Topics include applications in Barlow's disease, fibro-elastic deficiency, congenital heart anomalies, Anderson-Fabry disease, and post-cardiac transplantation, providing valuable insights into expanding TEER indications and overcoming anatomical...
Mitral interventions in shock
17 Nov 2025 – From PCR London Valves 2025
This session highlights the intricacies of mitral valve interventions in the context of cardiogenic shock. It addresses complex cases including left-to-right shunts post septal puncture, severe ischemic mitral insufficiency with small valve anatomy, emergency mitral TEER for papillary muscle rupture, and bridging strategies to surgery.
Tricuspid valve interventions in complex scenarios - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session delves into transcatheter interventions for the tricuspid valve in complex clinical scenarios. It covers techniques for native annular reduction via TEER, management of lead-related regurgitation, challenging cases of torrential regurgitation with device detachment, and innovative methods facilitating valve-in-ring implantation, enhancing procedural efficacy in tricuspid...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Author
POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?
02 Sep 2024
Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Author
Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials
14 Nov 2021
Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Author
ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines
29 Aug 2021
There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Author
Early intervention in patients with asymptomatic severe aortic stenosis and left ventricular myocardial fibrosis (EVOLVED)
30 Oct 2024
Ali Nazmi Calik provides his take on the EVOLVED trial presented by Marc Dweck at TCT 2024 in Washington.

Author